76 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
7 May 24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
4:02pm
for $160 Million Reimbursement Payment and Debt Repayment -
SAN DIEGO—(BUSINESS WIRE)— May 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage … .
◦Gossamer received a $160 million development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
& Other Indications
- Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory … will pay Gossamer $160 million as a development reimbursement. Additionally, Gossamer will be eligible to receive up to $146 million in regulatory milestones
S-1
EX-10.13
uc7fl 0i7m311g8g8
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.11
ay76h7onshmg
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.10
7utsznq
21 Dec 18
IPO registration
4:39pm
DRS
EX-10.9
p1ou2t9
11 Oct 18
Draft registration statement
12:00am
S-1
EX-10.8
s2yd1mu0jw y78
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.12
ljp 6yt5hd8d9lr
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.9
lo03z9
21 Dec 18
IPO registration
4:39pm
DRS
EX-10.8
ufe6h i6axv58wkd
11 Oct 18
Draft registration statement
12:00am
10-K
zksigehmqumrq7 e4y
22 Mar 19
Annual report
4:45pm